PUBLISHER: The Business Research Company | PRODUCT CODE: 1769647
PUBLISHER: The Business Research Company | PRODUCT CODE: 1769647
Lung cancer surgery equipment encompasses specialized medical devices and tools utilized during surgical procedures aimed at diagnosing, treating, and monitoring lung cancer. This category includes surgical instruments, imaging devices, biopsy tools, electrosurgical equipment, access devices, and patient monitoring systems, all designed to aid in tumor removal, reduce complications, and support patient recovery.
The primary categories of lung cancer surgery equipment consist of surgical instruments, access devices, imaging systems, electrosurgical tools, biopsy devices, and patient monitoring equipment. Surgical instruments are precision tools employed by surgeons to cut, clamp, grasp, or suture tissue during procedures. Common surgical approaches for lung cancer include lobectomy, pneumonectomy, wedge resection, video-assisted thoracoscopic surgery (VATS), and robotic-assisted surgery. These surgeries serve purposes such as diagnosis, treatment, and post-operative care or rehabilitation. The equipment is used across various end users, including hospitals, surgical clinics, ambulatory surgical centers, and research or academic institutions.
The lung cancer surgery equipment market research report is one of a series of new reports from The Business Research Company that provides lung cancer surgery equipment market statistics, including the lung cancer surgery equipment industry global market size, regional shares, competitors with the lung cancer surgery equipment market share, detailed lung cancer surgery equipment market segments, market trends, and opportunities, and any further data you may need to thrive in the lung cancer surgery equipment industry. This lung cancer surgery equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The lung cancer surgery equipment market size has grown strongly in recent years. It will grow from $3.49 billion in 2024 to $3.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historic period can be credited to factors such as the increasing prevalence of smoking, improved rates of early diagnosis, better surgical survival outcomes, greater adoption of lobectomy procedures, implementation of government cancer screening initiatives, expansion of hospital infrastructure, availability of skilled thoracic surgeons, a rise in open thoracotomy surgeries, limited surgical alternatives, and reimbursement support for cancer-related surgeries.
The lung cancer surgery equipment market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The projected growth during the forecast period can be attributed to the increasing incidence of lung cancer among non-smokers, a globally aging population, the expansion of minimally invasive surgical techniques, rising demand for robotic-assisted thoracic procedures, increased healthcare expenditures, better post-surgical recovery outcomes, a surge in outpatient thoracic operations, favorable regulatory approvals, heightened awareness driven by lung cancer campaigns, and broader insurance coverage in emerging markets. Key trends expected during this period include the adoption of robotic-assisted surgical platforms, application of AI in surgical planning, integration of 3D imaging into surgical procedures, advancement of smaller thoracoscopic instruments, improved visualization technologies, growth in remote surgical capabilities, real-time intraoperative navigation, utilization of smart staplers and instruments, development of personalized surgical tools using 3D printing, and implementation of AI-based systems for post-surgical monitoring.
The increasing prevalence of lung cancer is anticipated to drive the growth of the lung cancer surgery equipment market in the coming years. Lung cancer is a condition characterized by the uncontrolled growth of abnormal cells in the lungs, often caused by smoking or exposure to harmful environmental factors. The rise in lung cancer cases is primarily linked to increased exposure to risk factors such as tobacco smoke, air pollution, and occupational carcinogens, along with an aging global population. Lung cancer surgery equipment plays a critical role in diagnosing the disease, removing cancerous tissue, and facilitating post-operative care through accurate surgical procedures and effective patient monitoring. For example, in February 2025, the Cancer Council, an Australia-based non-profit organization, reported that an estimated 15,122 individuals were diagnosed with lung cancer in Australia in 2024, with the average age at diagnosis being 72. Lung cancer is the fifth most commonly diagnosed cancer in the country, and around one in 20 Australians is projected to be diagnosed with it by the age of 85. Hence, the rising prevalence of lung cancer is contributing to the expansion of the lung cancer surgery equipment market.
Leading companies in the lung cancer surgery equipment market are concentrating on the development of robotically assisted bronchoscopy devices to enhance the accuracy and safety of tumor localization and biopsy, facilitate access to difficult-to-reach lung nodules, and support early and precise lung cancer diagnosis. Robotically assisted bronchoscopy is an advanced procedure that employs robotic systems to guide a bronchoscope-a slender, flexible tube-into the lungs with greater accuracy and control compared to conventional manual methods. For instance, in March 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that its MONARCH QUEST system, an advanced robotic-assisted bronchoscopy technology, had received 510(k) clearance from the U.S. FDA. This system represents the next generation of the MONARCH Platform, developed to enhance lung cancer diagnosis through minimally invasive techniques. The MONARCH QUEST system integrates with the GE HealthCare OEC 3D mobile CBCT Imaging System, enabling real-time, intraprocedural 3D imaging. This integration significantly increases the precision of targeting lung nodules, particularly those located in hard-to-access regions of the lung.
In August 2024, Karl Storz SE & Co. KG, a medical technology company based in Germany, acquired Asensus Surgical Inc. for an undisclosed sum. Through this acquisition, Karl Storz intends to strengthen its position in the surgical robotics sector and broaden its offerings by incorporating Asensus Surgical's cutting-edge digital and robotic-assisted surgical technologies. Asensus Surgical Inc., headquartered in the United States, is a medical technology firm specializing in the development of surgical robots and digital solutions for a range of procedures, including lung cancer surgery.
Major players in the lung cancer surgery equipment market are Johnson & Johnson, Medtronic plc, Siemens Healthcare AG, Fujifilm Limited, GE Healthcare Technologies Inc., Boston Scientific Corporation, Zimmer Biomet Inc., Olympus Corporation, Intuitive Surgical Inc., Teleflex Incorporated, KARL STORZ GmbH & Co. KG, Integra LifeSciences Corporation, Elekta AB, Accuray Incorporated, Richard Wolf GmbH, Angiodynamics Inc., B. Braun Melsungen AG, Quantum Surgical SAS, Sontec Instruments Inc., Novadaq Technologies Inc.
North America was the largest region in the lung cancer surgery equipment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer surgery equipment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the lung cancer surgery equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The lung cancer surgery equipment market consists of sales of staplers, forceps, retractors, monopolar and bipolar electrosurgical generators, ultrasonic scalpels, and pulmonary needles. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Lung Cancer Surgery Equipment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on lung cancer surgery equipment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for lung cancer surgery equipment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer surgery equipment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.